Retatrutide – 10 MG

Retatrutide is a cutting-edge investigational peptide classified as a triple agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This unique triagonist mechanism positions Retatrutide at the forefront of advanced metabolic research, particularly in the areas of obesity, insulin resistance, and type 2 diabetes.

The 10MG vial of Retatrutide offers a potent dose suitable for extended protocols or blending into compounded formulations. Researchers have shown interest in this molecule due to its multifaceted action on appetite suppression, glucose metabolism, and fat oxidation.

Key Research Highlights:

• Enhanced Weight Loss: Demonstrated superior bodyweight reduction in early clinical trials compared to mono or dual agonists.

• Metabolic Benefits: Improves insulin sensitivity, lowers fasting glucose, and enhances energy expenditure.

• Appetite Control: Reduces hunger via central and peripheral pathways.

• Fat Oxidation: Encourages the body to utilise stored fat as fuel, aiding body recomposition.

Suggested Reconstitution:

• Reconstitute with 1–2ml of Bacteriostatic Water for Injection (BWFI).

• Store reconstituted solution in a refrigerated environment (2–8°C).

• For laboratory and research purposes only. Not for human consumption.

Why Researchers Choose Retatrutide 10MG:

• High-purity formulation ideal for long-term studies

• Trusted source with lab-certified COA

• Backed by leading pharmaceutical research, including data from Eli Lilly & Co.

⚠️ Note: This product is sold strictly for laboratory research purposes only. It is not approved for human or veterinary use.